Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

This study has been terminated.
(due to an altered benefit/risk assessment.)
Sponsor:
Collaborator:
Merck KGaA
Information provided by (Responsible Party):
Christof Kramm, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier:
NCT01517776
First received: January 11, 2012
Last updated: April 24, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)